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Abstract A large-scale, pooled analysis of safety data
from Wve Phase III clinical trials (including open-label
extensions of two of these studies) and two Phase III
open-label clinical trials of efalizumab was conducted
to explore whether arthropathy adverse events (AEs)
were associated with efalizumab treatment in patients
with moderate-to-severe chronic plaque psoriasis. Data
from patients who received subcutaneous injections of
efalizumab or placebo were stratiWed for analysis into
phases according to the nature and duration of treat-
ment. These included: the ‘Wrst treatment’ phase (0–12-
week data from patients who received either
efalizumab, 1 mg/kg once weekly, or placebo in the Wve
placebo-controlled studies); the ‘extended treatment’
phase (13–24-week data from seven trials for all
efalizumab-treated patients); and the ‘long-term treat-
ment’ phase (data from efalizumab-treated patients
who received treatment for up to 36 months in two
long-term trials). Descriptive statistics were performed
and the incidence of arthropathy AEs per patient-year
was calculated using 95% conWdence intervals (CIs).
During the Wrst treatment phase, a similar proportion
of patients had an arthropathy AE in the efalizumab
group (3.3%; 58/1740 patients) compared with the
placebo group (3.5%; 34/979 patients); the incidence of
arthropathy AEs per patient-year was 0.15 in the
efalizumab group (95% CI 0.11–0.19) and 0.16 in the
placebo group (95% CI 0.11–0.22). Analysis of Wrst
treatment phase data from one study (n = 793) showed
that the incidence of psoriatic arthropathy per patient-
year was lower in efalizumab-treated patients (0.10;
95% CI 0.05–0.18) than in those given placebo (0.17;
95% CI 0.08–0.30). During the extended treatment
phase, the incidence of arthropathy remained low
(0.17; 95% CI 0.14–0.22). Data from two long-term
studies showed that there was no increase in the inci-
dence of arthropathy AEs over time in patients treated
with efalizumab for up to 36 months. Patients who had
an arthropathy AE during treatment with efalizumab
appeared to be more likely to have a history of
arthropathy prior to treatment. Efalizumab does not
appear to increase the risk of arthropathy AEs com-
pared with placebo.
Keywords Arthropathy · Arthritis · Efalizumab · 
Psoriasis · Psoriatic arthritis
Introduction
Psoriasis is a chronic, immune-mediated, inXammatory
skin disorder that is currently incurable. Consequently,
the majority of people with psoriasis require long-term
treatment to maintain disease control. Traditional
immunosuppressive systemic treatments, such as aci-
tretin, methotrexate, cyclosporine, hydroxyurea, and
thioguanine, may be eVective in controlling psoriasis in
some patients but signiWcant toxicity and the need to
closely monitor patients limit the viability of these
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treatments for long-term, continuous use [23].
Recently developed systemic therapies that selectively
target speciWc pathways in the inXammatory cascade of
psoriasis generally have a much improved safety proWle
compared with traditional therapies [26].
Efalizumab (anti-CD11a; Raptiva®) is a recombi-
nant humanized monoclonal IgG1 antibody that has
been approved for the treatment of moderate-to-
severe chronic plaque psoriasis. It interferes with the
pathogenesis of psoriasis via multiple mechanisms,
including inhibition of T-lymphocyte traYcking and T-
lymphocyte activation and reactivation [1, 10, 11, 21,
25]. The safety and eYcacy proWle of efalizumab has
been established in numerous clinical trials, in which
more than 3,500 patients were enrolled and treatment
was assessed for up to 3 years [4–6, 12–17, 22].
Although psoriasis can be associated with the co-
morbidity of psoriatic arthritis, a minority of patients
with psoriasis (7–30%) will develop this joint disease
[27]. Nevertheless, psoriatic arthritis constitutes a
major consideration in patients who are receiving long-
term treatment for their psoriasis. A Nordic study of
more than 5,000 patients with psoriasis showed that
patients with arthritis exhibited greater impairment of
psoriasis-related quality of life (QoL), longer disease
duration, and greater self-reported disease severity,
compared with patients who had psoriasis but no co-
morbid arthritis [27].
A low incidence of arthropathy adverse events
(AEs; any form of joint disease) associated with
efalizumab treatment has been reported in both clini-
cal studies and routine clinical practice [8, 12]. How-
ever, anecdotal reports of arthropathy in routine
clinical practice have expressed concern that
efalizumab may be associated with exacerbation of
arthropathy [8]. To address this concern, we conducted
a large-scale pooled analysis of safety data from Wve
Phase III clinical trials (including open-label exten-
sions of two of these studies) and two Phase III open-
label clinical trials of efalizumab to explore whether
arthropathy AEs were associated with efalizumab
treatment in patients with psoriasis.
Methods
The primary objective of this pooled safety analysis
was to assess the incidence of arthropathy AEs in
patients who had received either efalizumab or pla-
cebo. Safety data were pooled from Wve randomized,
double-blind, placebo-controlled clinical trials (includ-
ing data from two open-label extension studies of two
of these trials) and two open-label clinical trials of
efalizumab [4–6, 12–17, 22]. Patients included in these
Phase III studies were aged ¸18 years and had moder-
ate-to-severe chronic plaque psoriasis, a psoriasis area
and severity index (PASI) score of ¸12 at screening,
and plaque psoriasis covering ¸10% of body surface
area. All patients were candidates for either systemic
anti-psoriatic therapy or had received systemic anti-
psoriatic therapy. Patients included in these trials
received subcutaneous injections with efalizumab, 1–
4 mg/kg once weekly or 2 mg/kg once-every-other
week, or placebo. Details of individual study method-
ologies are described in other publications [4–6, 12–17,
22].
Arthropathy AEs were deWned according to the Cod-
ing Symbols for Thesaurus of Adverse Reaction Terms
(COSTART) [3] preferred terms ‘arthritis’ and ‘arthro-
sis’, or the Medical Dictionary for Regulatory Activities
(MedDRA, http://www.meddramsso.com/NewWeb2003/
index.htm) preferred terms ‘arthritis not otherwise speci-
Wed (NOS)’, ‘psoriatic arthropathy’, ‘arthropathy NOS’,
‘monoarthritis’, ‘polyarthritis’, and ‘osteoarthritis NOS’.
Treatment groups analyzed
Due to the variety of study designs, Wve analyses were
considered: ‘Wrst-treatment phase’, ‘Wrst exposure
phase’, ‘extended treatment phase’, ‘re-treatment
phase’, and ‘long-term treatment’ (see Table 1).
It is worth noting that most of the studies included in
this pooled analysis were designed and conducted before
efalizumab had received regulatory approval and before
it was known that doses of more than 1 mg/kg once
weekly (the approved dose) did not confer additional
treatment beneWt (EMEA, Raptiva Summary of Product
Characteristics; FDA US, FDA Prescribing Information
for Raptiva). For this reason, only the efalizumab 1 mg/
kg once-weekly dose data are reported for the ‘Wrst treat-
ment phase’ of the analysis. Due to the wide variety of
study designs included in the pooled analysis, data for
patients receiving any dose of efalizumab are combined
for all other treatment phases analyzed.
The ‘Wrst treatment phase’ analysis included 0–12-
week data from patients in the Wve placebo-controlled
studies who received either efalizumab 1 mg/kg once
weekly or placebo. This analysis allows a comparison
between the efalizumab and placebo treatment groups.
The ‘Wrst exposure phase’ included 12-week data
from all studies in patients who had their Wrst exposure
to any dose of efalizumab and, thus, did not include
placebo data. This analysis was conducted to include
the maximum number of patients who received
efalizumab for their Wrst 12 weeks of treatment (i.e., it
included those patients who Wrst received efalizumabArch Dermatol Res (2006) 298:329–338 331
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treatment after crossing over from a placebo group, as
well as the patients who Wrst received efalizumab
during weeks 0–12).
The ‘extended treatment phase’ analysis included
13–24-week data in patients given any dose of
efalizumab who had already received efalizumab dur-
ing the Wrst treatment phase.
The ‘long-term treatment phase’ analysis included
all patients who received continuous long-term treat-
ment (up to 36 months) with any dose of efalizumab.
Data were analyzed in 12-week segments to assess
change in the incidence of arthropathy AEs over time.
This analysis included data from two long-term studies
[6,  15,  17], which were analyzed separately due to
diVerences in study design.
The ‘re-treatment phase’ analysis included all
patients who re-started treatment with efalizumab fol-
lowing a treatment-free observation period.
Statistical analyses
Descriptive statistics were used to explore the associa-
tion between efalizumab and the occurrence of
arthropathy AEs. Results are expressed as point-esti-
mates of the incidence rates (ratio of the number of
patients with an arthropathy AE to the total number of
patient-years at risk of an arthropathy AE) with their
95% conWdence intervals (CIs). Descriptive compari-
sons are provided; no formal statistical tests were per-
formed.
Analyses were also conducted to explore the rela-
tionship between onset of arthropathy AEs during
efalizumab treatment and a previous history of
arthropathy (reported as a narrative by patients at the
baseline visit) and the incidence of arthropathy AEs
and clinical response to efalizumab treatment [mea-
sured at 12 weeks using the Physician Global Assess-
ment (PGA) and PASI scales]. DiVerences in patient
and psoriasis characteristics at baseline were also com-
pared between patients who had arthropathy AEs and
those who did not. An additional analysis of data from
patients included in the Wrst treatment phase of the
study by Sterry et al. [22] (Table 1) was conducted to
assess the incidence of psoriatic arthropathy in these
patients. This was the only study to deWne arthropathy
AEs according to MedDRA; other studies used the
COSTART, which did not include ‘psoriatic arthropa-
thy’ speciWcally as a preferred term.
Baseline demographics and psoriasis characteristics
and the proportion of patients with a previous history
of arthropathy (as reported by patients at the baseline
visit) were tabulated by presence/absence of an
arthropathy event.
Results
The number of patients included in each of the pooled
safety analyses from each of the seven trials and two
open-label extensions is summarized in Table 1. Up to
3,394 patients received at least one dose of efalizumab.
A total of 2,719 patients were included in the Wrst treat-
ment phase analysis, of whom the majority (64%; 1,740
patients) received efalizumab 1 mg/kg per week; 979
patients (36%) received placebo. Efalizumab 2 mg/kg
per week regimen was given to 409 patients (15%) in
two of the Wve studies [12,  13]; consequently, these
patients were not included in the Wrst treatment analy-
sis. Patient demographics and baseline psoriasis char-
acteristics were similar between treatment groups in
the Wrst treatment phase (Table 2).
First treatment phase (weeks 0–12)
During the Wrst 12 weeks of treatment a similar pro-
portion of patients had an arthropathy AE in the
Table 2 Baseline demographic and disease characteristics for patients in the placebo-controlled Wrst treatment phase
BMI body mass index
a Due to missing height data, BMI was calculated for 971 patients in the placebo group, 1,719 patients in the efalizumab 1 mg//kg per
week group and 404 patients in the efalizumab 2 mg/kg per week group
Characteristics Placebo 
(n = 979)
Efalizumab 1 mg/kg per 
week (n = 1,740)
Efalizumab 2 mg/kg 
per week (n =4 0 9 )
Mean age (years), mean (SD) 45 (12) 45 (12) 45 (13)
Weight (kg), mean (SD) 90.0 (20.0)  89.4 (19.6) 93.6 (20.5)
Mean BMIa (kg/m2) 30.4 (6.4) 30.2 (6.3) 31.4 (6.6)
Race, n (%)
Caucasian 891 (91) 1,569 (90) 356 (87)
Other 88 (9) 171 (10) 53 (13)
Duration of psoriasis, mean 
number of years (SD)
19.2 (11.4) 19.1 (11.4) 17.6 (11.7)
History of arthritis, n (%) 286 (29.2) 529 (30.4) 141 (34.5)Arch Dermatol Res (2006) 298:329–338 333
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efalizumab 1 mg/kg group (3.3%) and the placebo
group (3.5%; Fig. 1a). Correspondingly, the incidence
of arthropathy AEs per patient-year was 0.15 in the
efalizumab 1 mg/kg group (95% CI 0.11–0.19) and 0.16
in the placebo group (95% CI 0.11–0.22; Fig. 1b). The
majority of the arthropathy AEs was mild-to-moderate
in intensity in both the efalizumab (41/58 events; 71%;
95% CI 57–82%) and placebo groups (31/34 events;
91%; 95% CI 76–98%).
The additional analysis of data from the study by
Sterry et al. [22] demonstrated that the incidence of
psoriatic arthropathy per patient-year was lower in the
group treated with efalizumab 1 mg/kg per week (0.10;
95% CI 0.05–0.18) than in the placebo group (0.17;
95% CI 0.08–0.30); the proportion of patients with pso-
riatic arthropathy was 2.3% (12/529 patients) in the
efalizumab group and 3.8% (10/264 patients) in the
placebo group.
First exposure phase
In total, 3,394 efalizumab-treated patients were
included in this analysis. A small proportion of patients
had an arthropathy AE (3.6%; Fig. 1a) and the inci-
Fig. 1 a Proportion of patients who had arthropathy adverse events (AEs) during each phase of the safety analysis and b incidence of
arthropathy AEs per patient-year for each phase334 Arch Dermatol Res (2006) 298:329–338
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dence of arthropathy AEs per patient-year was also
low (0.16; 95% CI 0.14–0.19; Fig. 1b).
The incidence of arthropathy AEs in this group of
patients was similar to that in the placebo group in the
Wrst treatment phase, as indicated by the overlap in
CIs.
Extended treatment phase (weeks 13–24)
In total, 2,111 patients were included in the extended
treatment phase analysis. During this phase, a low pro-
portion of patients had an arthropathy AE (3.8%;
Fig. 1a) and the incidence of arthropathy AEs per
patient-year was also low (0.17; 95% CI 0.14–0.22;
Fig. 1b). Overlap in the CIs indicates that the incidence
of arthropathy AEs in this group of patients was also
similar to that in the placebo group in the Wrst treat-
ment phase.
Long-term treatment phase
The results of two long-term studies were analyzed
separately to assess the incidence of arthropathy AEs
in patients treated with efalizumab. In both of these
studies (Fig. 2), there was no overall increase in the
incidence of arthropathy AEs over time. Furthermore,
the incidence of arthropathy remained similar to that
of the placebo group in the Wrst treatment phase and
stable between 12-week periods.
In total, 339 patients were included in the analysis of
the study by Gottlieb et al. [6]. These patients received
continuous treatment with efalizumab 2 mg/kg once
weekly for weeks 1–12 (Xuocinolone acetate or petro-
latum was co-administered during weeks 9–12), fol-
lowed by continuous maintenance treatment with
efalizumab 1 mg/kg once weekly for up to 36 months in
patients who had a ¸ 50% improvement in PASI score.
For months 3–15, the dose of efalizumab could be esca-
lated to 4 mg/kg per week for up to 4 weeks if clinically
indicated, then maintained at 2 mg/kg per week. Dur-
ing the entire study period, there was little variation in
the incidence of arthropathy AEs (range 0.06–0.19;
Fig. 2a). Reasons for discontinuation were diverse and
were representative of the overall population; refer to
Gottlieb et al. [6, 7] for details of discontinuations.
For the other long-term study, the analysis included
3-month data from 449 efalizumab-treated patients in
the placebo-controlled Wrst treatment phase of the
study [17] and data from 635 patients who entered the
open-label extension phase and received efalizumab
treatment [15]; 218 of the 635 patients included in the
open-label extension had switched from placebo to
efalizumab after completing the Wrst treatment phase.
Patients who entered the open-label extension phase
continued to receive, or initiated treatment with,
efalizumab 1 mg/kg once weekly for up to 15 months
continuously. As in the long-term study by Gottlieb
et al. [6], there was little variation in the incidence of
arthropathy AEs during the entire study period (range
0.06–0.12; Fig. 2b).
Re-treatment phase 
In total, 565 efalizumab-treated patients were included
in the re-treatment phase of the analysis. In this phase,
a lower proportion of patients had an arthropathy AE
(2.7%; Fig. 1a) compared with the Wrst treatment
phase, and the incidence of arthropathy AEs per
patient-year was also lower (0.12; 95% CI 0.07–0.19;
Fig. 1b). The incidence of arthropathy AEs in this
group of patients was lower than in the placebo group
in the Wrst treatment phase.
Baseline characteristics and previous history 
of arthropathy
There were no diVerences in baseline demographics or
disease characteristics between the patients who had
arthropathy AEs and those who did not. Patients who
experienced an arthropathy AE during treatment with
efalizumab appeared to be more likely to have a his-
tory of arthropathy prior to treatment. Of the patients
who never developed an arthropathy AE during
efalizumab treatment, 27% reported a previous history
of arthropathy compared with 59% in patients who did
have an arthropathy AE.
During the Wrst treatment phase, 88% (n = 34) and
76% (n = 79) of patients who developed an arthropa-
thy AE had a history of arthropathy prior to receiving
placebo or efalizumab 1 mg/kg once weekly, respec-
tively.
Arthropathy AEs and clinical response to efalizumab
Arthropathy AEs appeared to be less likely to occur in
patients who had a good clinical response to treatment
(¸75% improvement in PASI score; 2.3% of patients
had events) than in patients who had a partial response
(50–74% improvement in PASI score; 3.5% of patients
had events; Fig. 3) and non-responders (<50% improve-
ment in PASI score; 4.5% of patients had events). The
corresponding incidences of arthropathy AEs per
patient-year were 0.10 in patients with a good clinical
response (95% CI 0.05–0.18), 0.17 in patients with a par-
tial clinical response (95% CI 0.11–0.25), and 0.21 in
patients who did not respond (95% CI 0.15–0.28).Arch Dermatol Res (2006) 298:329–338 335
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When assessed using the PGA scale, arthropathy
AEs also appeared to be less likely to occur in patients
who had better clinical responses to treatment with
efalizumab (Fig. 3). During the extended treatment
phase, the incidence of arthropathy AEs per patient-
year was 0.17 in patients with responses categorized as
‘cleared’, ‘excellent’ or ‘good’ on the PGA scale (95%
CI 0.10–0.25) and 0.25 in patients with responses cate-
gorized as ‘fair’, ‘slight’, ‘unchanged’ or ‘worse’ on the
PGA scale (95% CI 0.17–0.35).
Discussion
The placebo-controlled results of this large-scale pooled
analysis of arthropathy data from seven clinical trials
show that efalizumab does not appear to increase the risk
of developing arthropathy AEs compared with placebo
during the Wrst 12 weeks of treatment. In addition, for
patients treated with efalizumab, the incidence of
arthropathy AEs did not appear to increase over time.
The proportion of patients who had an arthropathy AE
Fig. 2 Incidence of arthropathy AEs in long-term studies of pa-
tients treated with efalizumab a for up to 36 months and com-
pared indirectly with pooled placebo data from the Wrst treatment
(FT) phase [5, 6] and b for up to 15 months and compared with
the study’s placebo group during month 0–12 [15, 17]. *Following
the Wrst 3-month double-blind, placebo-controlled phase of this
study, patients in the placebo group who continued were switched
to open-label treatment with efalizumab. Consequently, the
month 6, 9, 12 and 15 results included patients who had received
placebo during the initial 3 months of the study336 Arch Dermatol Res (2006) 298:329–338
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within any 12-week treatment period was low (<4.1%)
through all treatment phases (Wrst treatment, Wrst
exposure, extended treatment, re-treatment, long-term
treatment).
Joint disease has also been reported as a side-eVect
of other approved biological treatments for psoriasis,
namely inXiximab (EMEA public statement on inXix-
imab,  http://www.emea.eu.int/pdfs/human/press/pus/4
44500en.pdf) [2, 18, 19], alefacept (Biogen safety presen-
tation on Alefacept to the FDA, http://www.fda.gov/
ohrms/dockets/ac/02/slides/3865S1_04_Biogen-Safety/
sld007.htm) [20, 24], and etanercept (EMEA ScientiWc
discussion for the approval of Enbrel, http://www.
emea.eu.int/humandocs/PDFs/EPAR/Enbrel/014600e
n6.pdf). Indeed, placebo-controlled studies of inXix-
imab and alefacept indicate that in patients with mod-
erate-to-severe psoriasis the incidence of arthralgia
(joint pain) is 7 and 5%, respectively (Biogen safety
presentation on Alefacept to the FDA, http://www.
fda.gov/ohrms/dockets/ac/02/slides/3865S1_04_Biogen-
Safety/sld007.htm) [18, 24]. Psoriatic arthritis has been
reported as serious treatment-related AE in three pla-
cebo-controlled studies of etanercept in the treatment
of chronic plaque psoriasis (incidence data have not
been published) (EMEA ScientiWc discussion for the
approval of Enbrel, http://www.emea.eu.int/human-
docs/PDFs/EPAR/Enbrel/014600en6.pdf). The inci-
dence of arthropathy AEs in the current analysis of
efalizumab appears to be similar to that for arthralgia
in studies of inXiximab and alefacept. Moreover, the term
‘arthropathy’, used in the current study encompasses a
variety of joint diseases, not just a single joint condition
such as arthralgia or psoriatic arthritis, and therefore
has greater potential to include more patients. How-
ever, this between-study comparison is indirect and
thus should be treated with caution. Moreover, no
arthropathy event (deWned by any of the MedDRA or
COSTART preferred terms) was excluded from the
analysis. Also, data from Wrst treatment phase of the
study by Sterry et al. [22] indicate that the proportion
of patients with psoriatic arthropathy speciWcally was
low (2.3%) in patients treated with efalizumab 1 mg/kg
per week—in fact, lower than in the placebo group
(3.8%). It should be noted, however, that psoriatic
arthropathy events were not conWrmed by a rheuma-
tologist—this is a potential limitation of the study.
However, the umbrella term ‘arthropathy’ was
designed to capture all joint diseases, including ‘psori-
atic arthropathy’. Also, the incidence of psoriatic
arthropathy in the study by Sterry et al. was in line with
the incidence of ‘arthropathy’ in the overall pooled
analysis.
To put the results of this pooled analysis, which by
its very nature included select patient populations
(determined by the inclusion/exclusion criteria and
study designs), in the context of routine clinical prac-
tice, post-marketing surveillance data were assessed.
During post-marketing surveillance of efalizumab,
which accounts for approximately 17,500 patient-years
to date, serious arthropathies requiring hospitalization
were reported with a frequency of about 4.8 per 1,000
patient-years in patients receiving efalizumab. It
Fig. 3 a Proportion of patients with an arthropathy AE by re-
sponse category on the psoriasis area and severity index (PASI)
and physician global assessment (PGA) scales and b incidence of
arthropathy AEs per patient-year by response category on the
PASI and PGA scalesArch Dermatol Res (2006) 298:329–338 337
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should be noted, however, that underreporting of AEs
in routine clinical practice setting may lead to an
underestimate of the true incidence of arthropathy.
For both the 12-week Wrst treatment and Wrst expo-
sure phases of the current analyses, the proportions of
patients reporting an arthropathy AE appeared to be
lower in the efalizumab groups than in the placebo
group in the Wrst treatment phase. Correspondingly,
the incidences of AEs per patient-year in these treat-
ment phases were also lower in the efalizumab groups
than that observed in the placebo group in the Wrst
treatment phase. However, the proportion of AEs that
were moderate or severe was greater in the efalizumab
groups than in the placebo groups; too few patients had
events to draw any meaningful conclusions.
During the extension phase (weeks 13–24), the inci-
dence of arthropathy AEs in efalizumab-treated
patients remained similar to the placebo group in the
Wrst treatment phase. Previous history of arthropathy
and poor clinical response may potentially indicate a
risk for occurrence of new arthropathy AEs during
treatment. Indeed, arthropathy AEs were most fre-
quent in patients who did not respond to therapy with
efalizumab or in patients with a history of arthropathy.
Importantly, the data from the two long-term stud-
ies of efalizumab indicate that the incidence of arthrop-
athy AEs remains stable and low for up to 3 years of
continuous treatment. These results, coupled with
eYcacy data showing that the clinical improvements of
the skin after 3 months of efalizumab therapy are
maintained throughout 36 months of continuous dos-
ing [5], support the suitability of efalizumab for the
chronic, continuous treatment of patients with psori-
asis. Reasons for patients’ discontinuations in the
36-month study by Gottlieb et al. [6, 7] were diverse
and representative of the overall population included
in this analysis and have been described previously.
When considering the long-term analysis of the
36-month study (Fig. 2a), it should be noted that the
number of patients who remained in the study
decreased over time. This discontinuation rate is not
unexpected for a study that is 3 years in duration but,
by month 36, there is a small number of patients on
which to base comparisons with the Wrst treatment
phase. Another factor that may confound between-
phase analysis comparisons was the possible use of
concomitant medications for psoriasis after the Wrst
treatment phase in the study by Gottlieb et al. [6],
which permitted the use of topical corticosteroids and
ultraviolet B phototherapy. Accordingly, it should be
noted that comparisons of the results between any of
the treatment phases of this analysis are observational
(i.e., not direct) but do conWrm the results of the
long-term treatment phase and the placebo-controlled
12-week Wrst treatment phase studies, suggesting that
the risk of joint disease is not increased with continued
efalizumab treatment and that the incidence of
arthropathy is low and similar to placebo. Further
investigation is needed to conWrm the results of this
preliminary analysis of arthropathy events during long-
term treatment with efalizumab.
In patients who re-started treatment for a further
12 weeks following an intervention-free period, the
proportion of patients who had an arthropathy AE was
lower than during the Wrst treatment phase; the same
was true for the incidence of arthropathy AEs per
patient-year in re-treated patients. Although this sce-
nario is likely to occur infrequently in clinical practice,
these data show that if a patient needs to stop (e.g.,
during pregnancy) and then restart treatment, there
appears to be no increased risk of arthropathy AEs.
Although arthritis in patients with psoriasis has a
signiWcant impact on QoL [9, 27], it can, in most cases,
be managed eVectively [8]. In the small minority of
patients who develop arthropathy during treatment,
the symptoms can be managed successfully with non-
steroidal anti-inXammatory drugs [8].
In conclusion, the results of this pooled analysis
show that efalizumab does not appear to increase the
risk of developing arthropathy AEs compared with
placebo. Long-term studies of efalizumab indicate that
the incidence of arthropathy AEs remains stable and
low for up to 3 years of continuous treatment.
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